Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial

Malignant pleural mesothelioma (MPM) is a highly aggressive pleural malignancy with poor survival with most patients succumbing to their disease within the first year following diagnosis. Precision medicine can provide important clinical insights that help to determine the prognosis at diagnosis, allow for increasing treatment intensity in selected patients and follow therapeutic responses. As a result, there is a clinical need for additional prognostic and predictive biomarkers for MPM therapy to aid in precision diagnostics for this patient population.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research